On Tuesday, Keros Therapeutics Inc (NASDAQ: KROS) opened higher 9.78% from the last session, before settling in for the closing price of $56.73. Price fluctuations for KROS have ranged from $27.31 to $73.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -40.00%. Company’s average yearly earnings per share was noted 11.60% at the time writing. With a float of $30.20 million, this company’s outstanding shares have now reached $39.26 million.
Let’s determine the extent of company efficiency that accounts for 136 employees. In terms of profitability, gross margin is -27.5%, operating margin of -31341.63%, and the pretax margin is -27890.94%.
Keros Therapeutics Inc (KROS) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Keros Therapeutics Inc is 25.43%, while institutional ownership is 79.02%. The most recent insider transaction that took place on Aug 13 ’24, was worth 11,002,500. In this transaction Director of this company sold 250,000 shares at a rate of $44.01, taking the stock ownership to the 119,522 shares. Before that another transaction happened on Aug 13 ’24, when Company’s Director sold 250,000 for $44.01, making the entire transaction worth $11,002,500. This insider now owns 119,522 shares in total.
Keros Therapeutics Inc (KROS) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -1.34 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -1.39) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.80% during the next five years compared to -111.11% drop over the previous five years of trading.
Keros Therapeutics Inc (NASDAQ: KROS) Trading Performance Indicators
Check out the current performance indicators for Keros Therapeutics Inc (KROS). In the past quarter, the stock posted a quick ratio of 19.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3881.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.21, a number that is poised to hit -0.78 in the next quarter and is forecasted to reach -5.16 in one year’s time.
Technical Analysis of Keros Therapeutics Inc (KROS)
Looking closely at Keros Therapeutics Inc (NASDAQ: KROS), its last 5-days average volume was 0.34 million, which is a drop from its year-to-date volume of 0.37 million. As of the previous 9 days, the stock’s Stochastic %D was 81.26%. Additionally, its Average True Range was 2.97.
During the past 100 days, Keros Therapeutics Inc’s (KROS) raw stochastic average was set at 70.91%, which indicates a significant decrease from 72.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.71% in the past 14 days, which was higher than the 47.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $59.61, while its 200-day Moving Average is $55.49. However, in the short run, Keros Therapeutics Inc’s stock first resistance to watch stands at $64.25. Second resistance stands at $66.23. The third major resistance level sits at $70.03. If the price goes on to break the first support level at $58.47, it is likely to go to the next support level at $54.67. Should the price break the second support level, the third support level stands at $52.69.
Keros Therapeutics Inc (NASDAQ: KROS) Key Stats
There are currently 40,507K shares outstanding in the company with a market cap of 2.52 billion. Presently, the company’s annual sales total 150 K according to its annual income of -152,990 K. Last quarter, the company’s sales amounted to 390 K and its income totaled -52,960 K.
